Shares of Savara Inc. (NASDAQ:SVRA – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.25.
Several equities analysts have commented on SVRA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Royal Bank Of Canada set a $10.00 target price on shares of Savara in a research note on Wednesday, October 7th. Citigroup reiterated a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. Wall Street Zen lowered shares of Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Finally, JPMorgan Chase & Co. initiated coverage on Savara in a research report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target on the stock.
Check Out Our Latest Report on Savara
Savara Stock Performance
Shares of SVRA opened at $4.99 on Friday. Savara has a fifty-two week low of $4.03 and a fifty-two week high of $7.01. The company has a current ratio of 8.55, a quick ratio of 10.13 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average is $4.96 and its 200-day moving average is $5.35.
Savara (NASDAQ:SVRA – Get Free Report) last issued its earnings results on Monday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01. On average, analysts anticipate that Savara will post -0.66 EPS for the current fiscal year.
Institutional Investors Weigh In On Savara
Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Savara in the 2nd quarter valued at approximately $76,966,000. Nantahala Capital Management LLC bought a new position in shares of Savara during the second quarter valued at $42,977,150. Spruce Street Capital LP bought a new position in shares of Savara during the second quarter valued at $21,267,868. Nan Fung Trinity HK Ltd. boosted its stake in shares of Savara by 1,088.3% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 1,842,350 shares of the company’s stock valued at $9,507,000 after purchasing an additional 1,687,310 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Savara in the 2nd quarter worth about $8,645,000. Institutional investors and hedge funds own 87.93% of the company’s stock.
Savara Company Profile
Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.
Featured Articles
- Five stocks we like better than Savara
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
